| Primary | Percentage of Participants Who Remained on Tocilizumab Treatment at 6 Months After Treatment Initiation | | | Posted | | Number | | percentage of participants | | Month 6 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Secondary | Percentage of Participants With RA Diagnosis | Percentage of participants was reported based on the timing RA was diagnosed. Timings included more than 5 years, less than 5 years. Participants with unknown timing were reported under "unknown". | | Posted | | Number | | percentage of participants | | Baseline up to Day 5 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |
| Secondary | Percentage of Participants With Different Body Mass Index (BMI) | BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m^2). BMI from 16 to 18.5 = underweight, BMI from 18.5 to 25= normal weight, BMI from 25 to 30= overweight, BMI from 30 to 40 = obese. | | Posted | | Number | | percentage of participants | | Baseline up to Day 5 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |
| Secondary | Percentage of Participants With Rheumatoid Factor Status | Percentage of participants with rheumatoid factor status was reported as "positive" or "negative". | | Posted | | Number | | percentage of participants | | Baseline up to Day 5 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |
| Secondary | Percentage of Participants With Anti-Citrullinated Cyclic Peptide (Anti-CCP) Status | Percentage of participants with anti-CCP status were reported as "positive", negative" and "unknown". | | Posted | | Number | | percentage of participants | | Baseline up to Day 5 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |
| Secondary | Percentage of Participants With a Reduction of at Least 2.6 Units in DAS28 From Baseline | The DAS28 score is a measure of the participants' disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], participant's global assessment (PtGA) of disease activity [visual analog scale (VAS): 0 millimeter (mm)=no disease activity to 100 mm=maximum disease activity] and the erythrocyte sedimentation rate (ESR). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*square root (sqrt) (TJC28) + 0.28*sqrt(SJC28) + 0.70*natural logarithm (ln) (ESR) + 0.014*PtGA of disease activity. A total possible score of 0 to approximately 10, with higher score indicating worse disease activity. A reduction of at least 2.6 units from Baseline in DAS28 was considered as significant clinical improvement. | | Posted | | Number | | percentage of participants | | Baseline, Month 1, 2, 3, 4, 5, 6 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |
| Secondary | Number of Participants Achieving a Response According to European League Against Rheumatism (EULAR) Criteria | Response was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 improvement from Baseline. Participants with a score less than or equal to (≤) 3.2 and DAS28 improvement of greater than (>) 1.2 points were assessed as having a 'good' response. Participants with a score ≤3.2 and DAS28 improvement of >0.6 to ≤1.2 points, score of >3.2 and ≤5.1 with DAS28 improvement of >0.6 to ≤1.2 points, score of >3.2 and ≤5.1 with DAS28 improvement of >1.2 points, score of >5.1 and DAS28 improvement of >1.2 points were assessed as having a 'moderate' response. Participants with a score ≤3.2 and DAS28 improvement of ≤ 0.6 points, score of >3.2 and ≤5.1 with DAS28 improvement of ≤ 0.6 points, score of >5.1 and DAS28 improvement of >0.6 to ≤1.2 points, score of >5.1 and DAS28 improvement of ≤ 0.6 points were assessed as having a 'no' response. | | Posted | | Number | | participants | | Baseline up to Month 6 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |
| Secondary | Number of Participants With Different Types of Simplified Disease Activity Index (SDAI) | The SDAI was calculated as [SJC (28 joints) + TJC (28 joints) + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity+CRP level(milligram/deciliter {mg/dL})]. VAS assessments: 0 centimeters (cm)=no disease activity to 10 cm=maximum disease activity'. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity. SDAI score ≤ 3.3 is 'remission', score > 3.3 and ≤ 11 is 'low disease activity', score > 11 and ≤ 26 is 'moderate disease activity', score > 26 is 'high disease activity'. SDAI was reported as 'not available' for participants with no data on physical/patient global assessment of disease activity. | | Posted | | Number | | participants | | Baseline up to Month 6 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |
| Secondary | Number of Participants With Different Types of Clinical Disease Activity Index (CDAI) | The CDAI was calculated as [SJC (28 joints) + TJC (28 joints) + VAS patient global assessment of disease activity + VAS physician global assessment of disease activity]. VAS assessments: 0 cm =no disease activity to 100 cm=maximum disease activity'. CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. CDAI score ≤ 2.8 is 'remission', score > 2.8 and ≤ 10 is 'low disease activity', score > 10 and ≤ 22 is 'moderate disease activity', score > 22 is 'high disease activity'. CDAI was reported as 'not available' for participants with no data on physical/patient global assessment of disease activity. | | Posted | | Number | | participants | | Baseline up to Month 6 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |
| Secondary | Percentage of Participants Achieving a Response According to ACR Criteria | ACR20/50/70 percent (%) response is defined as a ≥ 20%/50%/70% improvement (reduction) compared with baseline for both TJC28 and SJC28, as well as for three of the additional five ACR core set variables: Participant's assessment of pain over the previous 24 hours: using a VAS, left end of the line 0 cm=no pain to right end of the line 10 cm=unbearable pain; Patient's global assessment of disease activity and physician's global assessment of disease activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; health assessment questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or erythrocyte sedimentation rate]. | | Posted | | Number | | percentage of participants | | Month 1, 2, 3, 4, 5, 6 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |
| Secondary | Number of Participants With Reduction/Withdrawal of Disease-modifying Anti-rheumatic Drugs (DMARDs) and/or Corticosteroids | Participants with reduction/withdrawal of DMARDs and corticosteroids at baseline (before trial period) and up to Month 6 (during trial period) were reported. | | Posted | | Number | | participants | | Baseline, up to Month 6 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |
| Secondary | Change From Baseline in Physician Global Assessment of Disease Activity at Months 3 and 6 | Physician's global assessment of disease activity over the previous 24 hours was assessed using a VAS where left end of the line 0 mm=no disease activity to right end of the line 100 mm=maximum disease activity. | ITT. Here "number of participants analyzed" included evaluable participants for the outcome measure and "n" included evaluable participants at specified time point. | Posted | | Mean | Standard Deviation | mm | | Baseline, Months 3, 6 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |
| Secondary | Percentage of Participants With Tocilizumab Dose Modifications | | | Posted | | Number | | percentage of participants | | Baseline up to Month 6 | | | | ID | Title | Description |
|---|
| OG000 | Rheumatoid Arthritis Participants | Participants with moderate to severe RA according to the ACR criteria and the DAS28 who were on tocilizumab treatment within 8 weeks prior to start of study received tocilizumab in accordance with the licensed label recommendations, were observed for 6 months. The study was designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication was required. |
| |